Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Gwendolyn Wright

Nurse Practitioner, Gerontology Grand Blanc, MI Nurse Practitioner

NPI 1467832246 CMS profile 11114796

600 Health Park Blvd, Ste D, Grand Blanc, MI 48439

Open in the dashboard

General payments

$46,814

390 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gwendolyn Wright of Grand Blanc, MI is reported in the CMS Open Payments database as having received $46,814 across 390 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25,139 140
2024 General $11,686 128
2023 General $5,529 81
2022 General $3,219 30
2021 General $1,240 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gwendolyn Wright
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Gwendolyn Wright were reported at $25,139. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Gwendolyn Wright Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,240 $133 $44–$396 $132
2022 $3,219 $142 $48–$452 $149
2023 $5,529 $158 $53–$482 $160
2024 $11,686 $171 $55–$533 $164
2025 $25,139 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $14,580 60 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $13,546 92 payments
  3. AbbVie, Inc. $11,217 104 payments
  4. Genzyme Corporation $3,114 12 payments
  5. Ipsen Biopharmaceuticals, Inc $1,254 11 payments
  6. Janssen Biotech, Inc. $502 18 payments
  7. Regeneron Healthcare Solutions, Inc. $338 12 payments
  8. Gilead Sciences, Inc. $329 16 payments
  9. Pfizer Inc. $297 11 payments
  10. Regeneron Pharmaceuticals, Inc. $232 2 payments
  11. Other $1,405 52 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21,740 15 payments
  2. Food and Beverage $9,984 347 payments
  3. Travel and Lodging $7,563 18 payments
  4. Consulting Fee $7,416 5 payments
  5. Education $112 5 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $15,142 88 payments
  2. ENTYVIO $14,437 51 payments
  3. LINZESS $9,013 32 payments
  4. TRULANCE $5,923 31 payments
  5. RELISTOR $2,899 9 payments
  6. RINVOQ $1,204 42 payments
  7. Bylvay $1,111 4 payments
  8. SKYRIZI Immunology $727 24 payments
  9. SKYRIZI Immunology $586 17 payments
  10. TREMFYA $363 12 payments
  11. Other $3,590 149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,337

Median for Nurse Practitioner: 389

Drug cost

$337,365

Median for Nurse Practitioner: $21,885

Branded share of claims

28.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 157 $119,910
Creon Lipase/Protease/Amylase Brand 21 $68,590
Xifaxan Rifaximin Brand 20 $59,857
Mesalamine Generic 18 $20,183
Viberzi Eluxadoline Brand 11 $15,043
Motegrity Prucalopride Succinate Brand 18 $14,947
Lubiprostone Generic 102 $13,394
Colestipol Hcl Generic 37 $3,282
Mesalamine Dr Mesalamine Brand 12 $3,214
Omeprazole Generic 246 $2,776

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$14,564

Medicare's payments for the services billed

Medicare patients

169

Average age 73

Services billed

226

117 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 43%
Ischemic heart disease 36%
Chronic kidney disease 34%
Depression 34%
Atrial fibrillation 26%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $5,477
$5,477 — —
LINZESS
  • AbbVie, Inc. $3,542
  • Ironwood Pharmaceuticals, Inc $28
$3,570 157 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $399
$399 20 —
SKYRIZI
  • AbbVie, Inc. $399
$399 — —
RINVOQ
  • AbbVie, Inc. $288
$288 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

390 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record